Source disclosure: February 12, 2026
Veritas In Silico Inc. [130A.T]
TOKYO, Feb 12 (Pulse News Wire) – Veritas In Silico Inc. (130A.T) reported a wider net ¥425 million for the fiscal year ending December 2025 compared to ¥236 million in the previous year.
Operating revenue decreased to ¥91 million from ¥194 million, but operating expenses rose to ¥487 million from ¥425 million due to higher research and development costs. Key highlights included progress in joint drug discovery projects with major partners such as Otsuka Pharmaceutical and Mitsubishi Gas Chemical.
The company also secured patents for its ibVIS® technology and advanced its pipeline project targeting acute kidney failure prevention. However, significant impairment losses contributed to the overall decline in profitability.
For the fiscal year ending December 2026, Veritas expects revenues to reach ¥113 million while projecting a larger lower net profit of ¥567 million due to continued investment in internal research and development initiatives, relocation of its research institute, and equipment upgrades.
AI-translated content. 🔴 Confidence: Review recommended See terms • Original filing